Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of TG-2349 in Healthy Chinese Volunteers
NCT03610867Phase 1Completed
- Sponsor
- Dongguan HEC TaiGen Biopharmaceuticals
- Start
- Apr 2017
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of furaprevir in hepatitis C (HCV) (4 arms), sponsored by Dongguan HEC TaiGen Biopharmaceuticals. Primary endpoints: Maximum Plasma Concentration at 10 days, Time to Maximum Plasma Concentration at 10 days and 2 more. Started Apr 2017; status: completed.
02
Drugs
furaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03610867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03610867.